French biotechnology firm Lys Therapeutics has successfully raised over €25 million since its establishment in 2021 to advance its lead drug candidate, LYS241. This significant funding, which includes a major grant from The Michael J. Fox Foundation, will propel the novel antibody into clinical trials. The company aims to develop a new class of therapy for severe neurodegenerative and neurovascular diseases.
A Novel Therapeutic Approach
LYS241 is a first-in-class monoclonal antibody developed to target a specific neurovascular pathway known as the tPA-NMDAr axis. It is engineered to selectively block the harmful interaction between tissue plasminogen activator (tPA) and NMDA receptors. This innovative mechanism is designed to prevent neurotoxicity while preserving the essential physiological functions of the receptors.
The therapy's primary goal is to address fundamental pathological processes common to many neurological disorders. By targeting this pathway, LYS241 aims to mitigate blood-brain barrier dysfunction, reduce neuroinflammation, and prevent excitotoxicity. These actions could potentially halt or slow the progression of debilitating conditions like Parkinson's disease and ischemic stroke.
Significant Financial Backing
The financing round was bolstered by a substantial grant of over $5 million from The Michael J. Fox Foundation for Parkinson's Research. This contribution highlights the strong scientific validation behind the company's approach to treating Parkinson's disease. Additional support was provided by public institutions, including Bpifrance and the France 2030 plan, alongside private investors.
Lys Therapeutics also strengthened its shareholder base by welcoming several new strategic investors. These include Normandie Participation, the investment fund of the Normandy Region, and private equity firms TCD Capital and FIDAT Ventures. They join historical backers such as ZCUBE, the investment vehicle of the Zambon pharmaceutical group, and Philippe Bissay.
Advancing Towards Clinical Trials
With these newly secured resources, Lys Therapeutics is focused on advancing LYS241 toward human testing. The company will complete the final regulatory studies and scale up its manufacturing processes to support clinical development. These steps are critical for transitioning the promising preclinical candidate into a clinical-stage asset.
The company is preparing a biomarker-rich Phase 1a/1b clinical program to evaluate LYS241. This initial study will include cohorts of both healthy volunteers and patients with specific neurological indications. Its primary objectives are to assess the drug's safety profile, pharmacokinetics, and early signals of biological proof-of-concept.
Broad Therapeutic Potential
Recent preclinical data has demonstrated the potential of LYS241 to address key drivers of Parkinson's disease progression. The results indicate that the antibody can effectively counter blood-brain barrier dysfunction and neuroinflammation. This compelling evidence was a key factor in securing the significant grant from The Michael J. Fox Foundation.
The therapeutic potential of LYS241 extends beyond a single indication, embodying a "pipeline-in-a-product" strategy. The company is exploring its relevance in other synucleinopathies, including multiple system atrophy, with promising early data. In ischemic stroke, it is being developed to improve reperfusion quality and reduce treatment-related complications.
This successful fundraising effort marks a pivotal moment for Lys Therapeutics, providing the necessary capital to translate its innovative science into clinical reality. Dr. Manuel Blanc, CEO of the company, stated that the support validates their differentiated approach to neurovascular biology. The company is now positioned to develop what could become a new class of disease-modifying therapies for patients with significant unmet medical needs.